|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Octreotide
Test Code17567
CPT Codes
80299<br><strong>This test is not available for New York patient testing.</strong>
Preferred Specimen
3 mL serum collected in a red-top tube (no gel)
Patient Preparation
This test is useful only for those patients being treated with octreotide acetate. No special preparation is needed for this test. For optimal results, blood for this test should be drawn immediately before the patient's next injection of octreotide LAR (trough levels). Fasting is not required. Octreotide levels are not recommended for patients taking multiple, daily subcutaneous injections of Octreotide to guide therapy. However, patients receiving continuous subcutaneous infusion of Octreotide by pump can measure blood levels anytime while the pump is running. Levels may vary weight and sex. Additional lanreotide levels should be drawn in patients with evidence of tumor progression or loss of symptom control.
Minimum Volume
1 mL
Other Acceptable Specimens
Plasma collected in an EDTA (lavender-top) tube
Instructions
Collect 3 mL serum or EDTA plasma and separate as soon as possible. Octreotide is stable at room temperature for 3 days. Specimens can be stored room temperature, refrigerated, or frozen in dry ice. Minimum specimen size is 1 mL.
Transport Temperature
Frozen
Specimen Stability
Room temperature: 72 hours
Refrigerated: 30 days
Frozen: 8 months
Refrigerated: 30 days
Frozen: 8 months
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly icteric • Gross hemolysis • Grossly lipemic
Methodology
Direct Radioimmunoassay
FDA Status
This test was developed and its performance characteristics determined by Inter Science Institute. Values obtained with different methods, laboratories, or kits cannot be used interchangeably with the results on this report. The results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.
Setup Schedule
Set up: Varies; Report available: 8 business days
Reference Range
See Medical Report
Clinical Significance
Octreotide (Sandostatin,® Novartis Pharmaceutical Company) is used for the control of symptoms associated with functional neuroendocrine tumors. Frequent measurement of the octreotide levels may be useful in guiding therapy in patients with poorly controlled symptoms or those patients experiencing tumor growth during LAR therapy. Octreotide levels in blood need to be in a specific range to be effective. Measuring octreotide immediately prior to the monthly LAR injection will determine trough levels of the drug in your blood.